MENU
+Compare
CDT
Stock ticker: NASDAQ
AS OF
Sep 3, 04:59 PM (EDT)
Price
$1.20
Change
-$0.13 (-9.77%)
Capitalization
4.06M

CDT CDT Equity Inc Forecast, Technical & Fundamental Analysis

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients... Show more

CDT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CDT with price predictions
Sep 02, 2025

CDT in -6.99% downward trend, sliding for three consecutive days on August 29, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CDT declined for three days, in of 165 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CDT as a result. In of 70 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CDT turned negative on September 02, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 29 similar instances when the indicator turned negative. In of the 29 cases the stock turned lower in the days that followed. This puts the odds of success at .

The Aroon Indicator for CDT entered a downward trend on September 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CDT advanced for three days, in of 88 cases, the price rose further within the following month. The odds of a continued upward trend are .

CDT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.150) is normal, around the industry mean (19.852). P/E Ratio (0.000) is within average values for comparable stocks, (51.814). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.136). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (322.082).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CDT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CDT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
4995 Murphy Canyon Road
Phone
+1 760 471-8536
Employees
N/A
Web
https://www.conduitpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SBEV1.710.04
+2.11%
Splash Beverage Group
ITOS10.15N/A
N/A
iTeos Therapeutics
SF114.30-0.53
-0.46%
Stifel Financial Corp
AORT43.71-0.22
-0.50%
Artivion
MNY1.83-0.01
-0.54%
MoneyHero Limited

CDT and Stocks

Correlation & Price change

A.I.dvisor tells us that CDT and CMND have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CDT and CMND's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDT
1D Price
Change %
CDT100%
N/A
CMND - CDT
32%
Poorly correlated
-1.42%
UNBX - CDT
25%
Poorly correlated
-2.34%
VIR - CDT
23%
Poorly correlated
+1.21%
MRNA - CDT
23%
Poorly correlated
+0.42%
CVAC - CDT
22%
Poorly correlated
N/A
More